Literature DB >> 22340595

Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells.

Taru Muranen1, Laura M Selfors, Devin T Worster, Marcin P Iwanicki, Loling Song, Fabiana C Morales, Sizhen Gao, Gordon B Mills, Joan S Brugge.   

Abstract

The PI3K/mTOR-pathway is the most commonly dysregulated pathway in epithelial cancers and represents an important target for cancer therapeutics. Here, we show that dual inhibition of PI3K/mTOR in ovarian cancer-spheroids leads to death of inner matrix-deprived cells, whereas matrix-attached cells are resistant. This matrix-associated resistance is mediated by drug-induced upregulation of cellular survival programs that involve both FOXO-regulated transcription and cap-independent translation. Inhibition of any one of several upregulated proteins, including Bcl-2, EGFR, or IGF1R, abrogates resistance to PI3K/mTOR inhibition. These results demonstrate that acute adaptive responses to PI3K/mTOR inhibition in matrix-attached cells resemble well-conserved stress responses to nutrient and growth factor deprivation. Bypass of this resistance mechanism through rational design of drug combinations could significantly enhance PI3K-targeted drug efficacy. Copyright Â
© 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22340595      PMCID: PMC3297962          DOI: 10.1016/j.ccr.2011.12.024

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  78 in total

1.  Identification of eukaryotic mRNAs that are translated at reduced cap binding complex eIF4F concentrations using a cDNA microarray.

Authors:  G Johannes; M S Carter; M B Eisen; P O Brown; P Sarnow
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-09       Impact factor: 11.205

Review 2.  Translational control in stress and apoptosis.

Authors:  Martin Holcik; Nahum Sonenberg
Journal:  Nat Rev Mol Cell Biol       Date:  2005-04       Impact factor: 94.444

Review 3.  Apoptotic cell signaling in cancer progression and therapy.

Authors:  Jessica Plati; Octavian Bucur; Roya Khosravi-Far
Journal:  Integr Biol (Camb)       Date:  2011-02-22       Impact factor: 2.192

4.  IRES-mediated functional coupling of transcription and translation amplifies insulin receptor feedback.

Authors:  Michael T Marr; Joseph A D'Alessio; Oscar Puig; Robert Tjian
Journal:  Genes Dev       Date:  2007-01-15       Impact factor: 11.361

5.  HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment.

Authors:  Britta Weigelt; Alvin T Lo; Catherine C Park; Joe W Gray; Mina J Bissell
Journal:  Breast Cancer Res Treat       Date:  2009-08-22       Impact factor: 4.872

6.  Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts.

Authors:  Chad J Creighton; Suleiman Massarweh; Shixia Huang; Anna Tsimelzon; Susan G Hilsenbeck; C Kent Osborne; Jiang Shou; Luca Malorni; Rachel Schiff
Journal:  Cancer Res       Date:  2008-09-15       Impact factor: 12.701

7.  Oncogenic mutations of PIK3CA in human cancers.

Authors:  Yardena Samuels; Victor E Velculescu
Journal:  Cell Cycle       Date:  2004-10-12       Impact factor: 4.534

8.  Eukaryotic translation initiation machinery can operate in a bacterial-like mode without eIF2.

Authors:  Ilya M Terenin; Sergey E Dmitriev; Dmitry E Andreev; Ivan N Shatsky
Journal:  Nat Struct Mol Biol       Date:  2008-07-06       Impact factor: 15.369

9.  An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1.

Authors:  Carson C Thoreen; Seong A Kang; Jae Won Chang; Qingsong Liu; Jianming Zhang; Yi Gao; Laurie J Reichling; Taebo Sim; David M Sabatini; Nathanael S Gray
Journal:  J Biol Chem       Date:  2009-01-15       Impact factor: 5.157

10.  Int6 regulates both proteasomal degradation and translation initiation and is critical for proper formation of acini by human mammary epithelium.

Authors:  J Suo; S J Snider; G B Mills; C J Creighton; A C Chen; R Schiff; R E Lloyd; E C Chang
Journal:  Oncogene       Date:  2010-10-04       Impact factor: 9.867

View more
  206 in total

Review 1.  Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer.

Authors:  D Merino; S W Lok; J E Visvader; G J Lindeman
Journal:  Oncogene       Date:  2015-08-10       Impact factor: 9.867

2.  PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1.

Authors:  Hiromichi Ebi; Carlotta Costa; Anthony C Faber; Madhuri Nishtala; Hiroshi Kotani; Dejan Juric; Patricia Della Pelle; Youngchul Song; Seiji Yano; Mari Mino-Kenudson; Cyril H Benes; Jeffrey A Engelman
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-10       Impact factor: 11.205

3.  Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia.

Authors:  Marina Y Konopleva; Roland B Walter; Stefan H Faderl; Elias J Jabbour; Zhihong Zeng; Gautam Borthakur; Xuelin Huang; Tapan M Kadia; Peter P Ruvolo; Jennie B Feliu; Hongbo Lu; Lakiesha Debose; Jan A Burger; Michael Andreeff; Wenbin Liu; Keith A Baggerly; Steven M Kornblau; L Austin Doyle; Elihu H Estey; Hagop M Kantarjian
Journal:  Clin Cancer Res       Date:  2014-02-28       Impact factor: 12.531

Review 4.  Using reverse-phase protein arrays as pharmacodynamic assays for functional proteomics, biomarker discovery, and drug development in cancer.

Authors:  Yiling Lu; Shiyun Ling; Apurva M Hegde; Lauren A Byers; Kevin Coombes; Gordon B Mills; Rehan Akbani
Journal:  Semin Oncol       Date:  2016-06-15       Impact factor: 4.929

5.  mTORC1 inhibition restricts inflammation-associated gastrointestinal tumorigenesis in mice.

Authors:  Stefan Thiem; Thomas P Pierce; Michelle Palmieri; Tracy L Putoczki; Michael Buchert; Adele Preaudet; Ryan O Farid; Chris Love; Bruno Catimel; Zhengdeng Lei; Steve Rozen; Veena Gopalakrishnan; Fred Schaper; Michael Hallek; Alex Boussioutas; Patrick Tan; Andrew Jarnicki; Matthias Ernst
Journal:  J Clin Invest       Date:  2013-01-16       Impact factor: 14.808

Review 6.  PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects.

Authors:  Rosalin Mishra; Hima Patel; Samar Alanazi; Mary Kate Kilroy; Joan T Garrett
Journal:  Int J Mol Sci       Date:  2021-03-27       Impact factor: 5.923

7.  Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling.

Authors:  Marie Will; Alice Can Ran Qin; Weiyi Toy; Zhan Yao; Vanessa Rodrik-Outmezguine; Claudia Schneider; Xiaodong Huang; Prashant Monian; Xuejun Jiang; Elisa de Stanchina; José Baselga; Ningshu Liu; Sarat Chandarlapaty; Neal Rosen
Journal:  Cancer Discov       Date:  2014-01-16       Impact factor: 39.397

8.  Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers.

Authors:  Chaoyang Sun; Yong Fang; Jun Yin; Jian Chen; Zhenlin Ju; Dong Zhang; Xiaohua Chen; Christopher P Vellano; Kang Jin Jeong; Patrick Kwok-Shing Ng; Agda Karina B Eterovic; Neil H Bhola; Yiling Lu; Shannon N Westin; Jennifer R Grandis; Shiaw-Yih Lin; Kenneth L Scott; Guang Peng; Joan Brugge; Gordon B Mills
Journal:  Sci Transl Med       Date:  2017-05-31       Impact factor: 17.956

9.  Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancers.

Authors:  Pradeep Chaluvally-Raghavan; Fan Zhang; Sunila Pradeep; Mark P Hamilton; Xi Zhao; Rajesha Rupaimoole; Tyler Moss; Yiling Lu; Shuangxing Yu; Chad V Pecot; Miriam R Aure; Sylvain Peuget; Cristian Rodriguez-Aguayo; Hee-Dong Han; Dong Zhang; Avinashnarayan Venkatanarayan; Marit Krohn; Vessela N Kristensen; Mihai Gagea; Prahlad Ram; Wenbin Liu; Gabriel Lopez-Berestein; Philip L Lorenzi; Anne-Lise Børresen-Dale; Koei Chin; Joe Gray; Nelson J Dusetti; Sean E McGuire; Elsa R Flores; Anil K Sood; Gordon B Mills
Journal:  Cancer Cell       Date:  2014-12-08       Impact factor: 31.743

Review 10.  AKT/PKB Signaling: Navigating the Network.

Authors:  Brendan D Manning; Alex Toker
Journal:  Cell       Date:  2017-04-20       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.